Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

June 5, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Complement Tissue injury and its protection during COVID-19

Is Diabetes as dangerous and wicked as COVID-19?

Tata Innovation Fellowship 2020-21 – Life Sciences & Biotechnology

Complement Tissue injury and its protection during COVID-19
  • BiotechToday
  • World

Complement Tissue injury and its protection during COVID-19

bioxone October 7, 2020October 7, 2020

Srilagna Sarkar, Amity University Kolkata

Even though the novel coronavirus disease originates in the lungs, it may extend to other tissues and cause organ damage including cardiac injury, multiorgan failure, and even acute kidney injury, associating it with an increased risk of death. Although the COVID-19 tissue injury is not primarily mediated by any viral infection, it may result in inflammatory host immune response, driving hypercytokinemia and other aggressive inflammation affecting lung parenchymal cell, also diminishing the oxygen rate uptake by the lungs, endothelial cells damage resulting in endothelium and thrombotic evens with intravascular coagulation. 

The complement system signifies the primary responsibility of the host immune system of SARS-COV-2 infection, but several pieces of evidence show there is unstrained activation of complement induced in the lungs and other tissues play a major role in acute and chronic inflammation including thrombus formation, intravascular coagulation, ultimately leading to death due to organ failure.

As protection from tissue injury, besides the efforts on finding an effective antivirus therapy, emphasis on limited tissue injury in severe COVID-19 should be expanded. As, Gonzalez-Nicholas et al – has emphasized, tissue-protective cilastatin against hyper inflammation and its potential to limit virus entry in target cells. However, the fact that COVID-19 patients are frequently with antibiotics may generate early data by conventionally treated COVID-19 patients and will give trials randomizing patients to receive their imipenem – whether cilastatin or some substitute antibiotic. As proof of Cilastatin tissue protection will require testing the compound itself.

Also read: Is Diabetes as dangerous and wicked as COVID-19?

Source: https://academic.oup.com/ckj/advance-article/doi/10.1093/ckj/sfaa196/5917718

  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged acute kidney injury cilastatin complement complementation COVID-19 host immunity immunity inflammation response SARS-CoV-2 suppression Tissue injury Tissue injury and COVID-19 Tissue injury and its protection during COVID-19 tissue protection

2 thoughts on “Complement Tissue injury and its protection during COVID-19”

  1. Sohinee roy says:
    October 7, 2020 at 7:27 am

    Nice 👍

    Reply
  2. Barsha Bera says:
    October 10, 2020 at 9:42 am

    Good…. keep it up…. 👌👌👌

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • Job and Internship
  • Signaling Pathway

Tata Innovation Fellowship 2020-21 – Life Sciences & Biotechnology

bioxone October 7, 2020

-Shristi Sharma, Team bioXone The details on Tata Innovation Fellowship 2020-21 have been announced. Check the official notification for the Tata Innovation Fellowship 2020-2021 below. DBT India has released the official notification for Tata Innovation Fellowship 2021. Ph.D. Life sciences candidates and MSc Biotechnology candidates eligible to apply for Tata Innovation Fellowship 2021 as per […]

Related Post

  • BiotechToday
  • World

Transcriptomic analysis of etiology behind fatality in HIV patients

BioTech Today June 22, 2021June 21, 2021

Kanikah Mehndiratta Transcriptomic analysis has been a recent approach to identify biomarkers associated with normal or diseased physiology in patients. An obvious approach to targeting any infection or disease through treatment strategies or prophylaxis requires a proper understanding of the mechanisms of its pathogenesis. Researching on better and more effective treatment approaches towards a deadly […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Moderna’s mRNA–1273 granted emergency use authorization by FDA

bioxone December 28, 2020December 28, 2020

Prama Ghosh, Amity University Kolkata The Food and Drug Administration announced granted emergency use authorization to Moderna’s mRNA–1273, it’s COVID-19 vaccine for use in individuals 18 and older Friday night, the second vaccination against the coronavirus in the United States one week after the agency authorized a similar vaccine from Pfizer and BioNTech. Moderna’s vaccine […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Tiny bacteria know how to change to survive inside humans

BioTech Today January 28, 2022January 28, 2022

Debarati Basu, Makaut WB The microorganisms that inhabited our mouths are inclusively known as the oral microbiome. These microorganisms (tiny bacteria, etc.) influence our general wellbeing in numerous ways that are not yet completely comprehended. A few microorganisms cause inflammation, which can lead to periodontitis and other foundational infections, like cardiovascular disease and diabetes. Other […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy